Mission: AtriCure’s mission of reducing the global atrial fibrillation (Afib) epidemic and healing the lives of those affected.
AtriCure, Inc. is a medical device company that provides innovative solutions designed to decrease the global Afib epidemic. AtriCure’s Isolator Synergy Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage Management (LAAM) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. AtriCure believes electrophysiologists and cardiothoracic surgeons are adopting its technologies for the treatment of Afib and reduction of Afib related complications. Afib affects more than 33 million people worldwide.
As AtriCure’s product portfolio grows, so does its team. These hard-working, dedicated individuals are carefully selected based on expertise and reputation within the medical device industry. Team members have joined AtriCure to fulfill not only its mission, but also to realize their own. Today, over 500 employees work for AtriCure in a variety of capacities.
AtriCure is a growing company full of innovative professionals looking to make a difference in the lives of our patients. Occasionally, we have openings in the following departments:
Additionally, AtriCure utilizes temporary staff, co-ops, interns and independent contractors.
Michael Hooven and his wife, Sue Spies, co-founded ENABLE Medical Corporation. ENABLE Medical’s first product was a pair of radiofrequency energized surgical scissors designed to harvest saphenous veins in cardiac bypass procedures, IMA harvesting, and general surgical applications.
In November, AtriCure was established as an independent business focused on atrial fibrillation. ENABLE Medical provided contract development and manufacturing services to AtriCure.
The AtriCure bipolar ablation system was cleared by the U.S. FDA for the ablation of soft tissues.
The Journal of Thoracic and Cardiovascular Surgery published the first article on AtriCure devices--"Chronic Transmural Atrial Ablation by Using Bipolar Radiofrequency Energy on the Beating Heart." The article was authored by Sunil M. Prasad, M.D., Hersh S. Maniar, M.D., Richard B. Schuessler, Ph.D., and Ralph J. Damiano, Jr., M.D.
On August, 5, 2005, AtriCure became a publicly traded company on the NASDAQ Stock Exchange. Prior to AtriCure's initial public offering, AtriCure acquired ENABLE Medical and all of its personnel, facilities and other assets.
AtriCure opened its European office in the Netherlands.
AtriCure entered the cryosurgical market when it acquired the Frigitronics cryogenic product line from CooperSurgical, Inc.
AtriCure launched the EXCLUDE trial to evaluate the safety and efficacy of the AtriClip LAA Exclusion System for occluding the left atrial appendage.
The Isolator Coolrail Linear Pen was cleared by FDA for ablation of cardiac tissue with radiofrequency energy during cardiac surgery.
The first patient was enrolled in the ABLATE Study. The primary objective of this study is to evaluate the safety and efficacy of the AtriCure Bipolar System in performing pulmonary vein isolations and the atrial “connecting lesions” of the Maze procedure.
AtriCure’s cryoICE and cryo1 cryoablation probes were cleared by FDA for the cryosurgical treatment of cardiac arrhythmias.
The AtriClip LAA Exclusion System was cleared by FDA for the occlusion of the left atrial appendage, under direct visualization, in conjunction with other open cardiac surgical procedures.
The first patient was enrolled in AtriCure’s DEEP AF feasibility study. The study evaluated the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients presenting with persistent atrial fibrillation or longstanding persistent atrial fibrillation.
Following successful completion of the ABLATE study, AtriCure’s Isolator Synergy ablation system became the first device approved by FDA for the treatment of persistent or longstanding persistent atrial fibrillation.
AtriCure partnered with Dr. James L. Cox and launched the Maze IV training program in the United States to educate healthcare providers on the safe and effective use of the AtriCure Isolator Synergy System in the treatment of non-paroxysmal forms of atrial fibrillation.
AtriCure expanded the Maze IV training program to Europe.
A milestone was reached as AtriCure surpassed 150,000 ablations and over 200,000 patients treated. The Minneapolis office was also opened.
AtriCure acquired Endoscopic Technologies, Inc. (Estech), which expanded AtriCure's product portfolio with the addition of the Fusion Surgical Ablation System and a comprehensive suite of cardiac surgery instruments. As a result, AtriCure opened the San Ramon office.
Launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain management. AtriCure’s cryoICE is the first FDA cleared cryo ablation probe for the treatment of cardiac arrhythmias and for the temporary ablation of peripheral nerves to block pain.
A milestone in LAA management is reached with more than 50,000 patients worldwide having been treated with AtriClip LAA Exclusion System.
AtriCure acquired nContact Surgical, LLC.
On November 3, 2015, the Cincinnati headquarters opened its newly built facility in Mason, Ohio.
AtriCure announces first patient enrolled in international Afib clinical study, Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation (CEASE-AF).
First patient enrolled in ATLAS clinical study. This observational study explores the use of the AtriClip device to decrease complications associated with Post-Operative Afib (POAF) by targeting specific cardiac surgery patient populations at the highest risk of developing POAF.
The cryoFORM cryoablation probe was made commercially available in the U.S. This probe offers increased probe flexibility to adapt to a variety of surgical ablation procedures.
A new AtriClip device, called the AtriClip PRO2 was made commercially available in the U.S and European markets. This new device has increased functionality that enhances the capability of occluding the left atrial appendage in minimally-invasive cardiac surgeries.
Gained approval for the AtriClip products and cryoICE platform in Japan.
First patient enrolled in the FROST trial. This clinical study examines the cryoICE Cryoablation Probe, CRYO2, for pain management in post thoracic procedures via intercostal cryoanalgesia.
STS 2017 Clinical Practice Guidelines for Surgical Treatment of Afib changed surgical ablation at the time of structural heart surgery from a Class II to a Class I recommendation. The recommendations have gone from it is “reasonable” to do an ablation in Afib patients undergoing major types of structural heart surgery to it is “recommended” to do an ablation.
A milestone was reached as AtriCure surpassed 100,000 AtriClip LAA Exclusion System devices sold worldwide.
The AtriClip PRO•V Device has been made commercially available in the U.S. The new device offers several modifications which enable easier navigation and placement when operating in minimally-invasive surgery (MIS) environments.
Fun Facts about our global presence:
What Makes AtriCure Special?
Employees are saying...
~ What makes AtriCure special is the passion that people have here, the dedication to their work.
~ Everybody is pushing to get things done, making sure we're doing innovative new things, making sure that everything is done correctly, because the end goal is really to make patient's lives better.
~ AtriCure has fostered a culture of people who care, a culture of people who trust each other, that work well interdependently, people that work diligently knowing that patients with Afib and their families are waiting for treatment.
~ There is a collective goal amongst all of our employees that we make and produce a quality product.
I have been working at AtriCure full-time (More than a year)
AtriCure is a growing organization with a lot of great opportunities for growth and development for employees. There is a good benefit package available and a strong Wellness initiative throughout the company. The culture of the company is one reason most enjoy working at AtriCure and the Patient First focus what drives us daily to do great work in the Medial Device industry.
With the high level of growth, there are areas where the company is trying to catch up and make improvements to handle the higher level of business and number of new employees. This is causing some systems to be out dated and some inefficiencies to be apparent.
Advice to Management
Even though we're busy, make sure that new employees get the training and attention they need within their first few months to ensure they are well acclimated and ready to contribute.
I applied online. The process took 6 days. I interviewed at AtriCure (Blaine, MN) in June 2016.
Phone interview with human resources, casual in person interview with CEO and phone interview with hiring manager.
Typical questions from HR (walked through resume, why did I leave, what did I like/not like about the positions, what did my team look like, etc). Meeting with CEO was a chance to ask him questions and hear about his vision for the company. Those parts of the interview process were great.